Feasibility of Allografting in Patients with Advanced Acute Lymphoblastic Leukemia After Salvage Therapy With Inotuzumab Ozogamicin

Inotuzumab ozogamicin (IO) is a CD22 monoclonal antibody that targets B lymphocytes in early stages of development, successfully inducing remission in patients with relapsed acute lymphoblastic leukemia (ALL). We report our experience of 26 patients who were treated with IO followed by allogeneic st...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Kebriaei, Partow, Wilhelm, Kaci, Ravandi, Farhad, Brandt, Mark, de Lima, Marcos, Ciurea, Stefan, Worth, Laura, O’Brien, Susan, Thomas, Deborah, Champlin, Richard E., Kantarjian, Hagop
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2013
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4102410/
https://ncbi.nlm.nih.gov/pubmed/23313065
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2012.12.003
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge